159 related articles for article (PubMed ID: 23254425)
1. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection.
Han S; Kim J; Yim H; Hur J; Song W; Lee J; Jeon S; Hong T; Woo H; Yim DS
Antimicrob Agents Chemother; 2013 Feb; 57(2):1006-11. PubMed ID: 23254425
[TBL] [Abstract][Full Text] [Related]
2. Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Sinnollareddy MG; Roger C; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2016 Nov; 60(11):6550-6557. PubMed ID: 27550344
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.
Rodríguez-Tudela JL; Almirante B; Rodríguez-Pardo D; Laguna F; Donnelly JP; Mouton JW; Pahissa A; Cuenca-Estrella M
Antimicrob Agents Chemother; 2007 Oct; 51(10):3599-604. PubMed ID: 17646421
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152
[No Abstract] [Full Text] [Related]
5. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.
Gharibian KN; Mueller BA
Clin Nephrol; 2016 Jul; 86(7):43-50. PubMed ID: 27251341
[TBL] [Abstract][Full Text] [Related]
6. Plasma and tissue concentrations of fluconazole and their correlation to breakpoints.
Pittrow L; Penk A
Mycoses; 1997; 40(1-2):25-32. PubMed ID: 9260478
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.
Patel K; Roberts JA; Lipman J; Tett SE; Deldot ME; Kirkpatrick CM
Antimicrob Agents Chemother; 2011 Dec; 55(12):5868-73. PubMed ID: 21930888
[TBL] [Abstract][Full Text] [Related]
8. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
Andes D; van Ogtrop M
Antimicrob Agents Chemother; 1999 Sep; 43(9):2116-20. PubMed ID: 10471550
[TBL] [Abstract][Full Text] [Related]
9. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.
Louie A; Banerjee P; Drusano GL; Shayegani M; Miller MH
Antimicrob Agents Chemother; 1999 Dec; 43(12):2841-7. PubMed ID: 10582869
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis.
Sinnollareddy MG; Roberts MS; Lipman J; Lassig-Smith M; Starr T; Robertson T; Peake SL; Roberts JA
Antimicrob Agents Chemother; 2016 Feb; 60(2):827-32. PubMed ID: 26596947
[TBL] [Abstract][Full Text] [Related]
11. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
[TBL] [Abstract][Full Text] [Related]
12. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
Pfaller MA; Diekema DJ; Sheehan DJ
Clin Microbiol Rev; 2006 Apr; 19(2):435-47. PubMed ID: 16614256
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis.
Gonzalez JM; Rodriguez CA; Zuluaga AF; Agudelo M; Vesga O
PLoS One; 2015; 10(11):e0141872. PubMed ID: 26536105
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of fluconazole in young infants.
Wade KC; Wu D; Kaufman DA; Ward RM; Benjamin DK; Sullivan JE; Ramey N; Jayaraman B; Hoppu K; Adamson PC; Gastonguay MR; Barrett JS;
Antimicrob Agents Chemother; 2008 Nov; 52(11):4043-9. PubMed ID: 18809946
[TBL] [Abstract][Full Text] [Related]
15. EUCAST technical note on fluconazole.
European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)
Clin Microbiol Infect; 2008 Feb; 14(2):193-5. PubMed ID: 18070130
[No Abstract] [Full Text] [Related]
16. External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models.
Hwang MF; Beechinor RJ; Wade KC; Benjamin DK; Smith PB; Hornik CP; Capparelli EV; Duara S; Kennedy KA; Cohen-Wolkowiez M; Gonzalez D
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893774
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.
Cojutti PG; Lugano M; Righi E; Della Rocca G; Bassetti M; Hope W; Pea F
Eur J Clin Pharmacol; 2018 Nov; 74(11):1449-1459. PubMed ID: 30032414
[TBL] [Abstract][Full Text] [Related]
18. Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors.
Lacassin F; Damond F; Chochillon C; Longuet P; Lebras J; Vilde JL; Leport C
Antimicrob Agents Chemother; 1996 Aug; 40(8):1961-3. PubMed ID: 8843316
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis.
Stott KE; Beardsley J; Kolamunnage-Dona R; Castelazo AS; Kibengo FM; Mai NTH; Tùng NLN; Cuc NTK; Day J; Hope W
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914943
[TBL] [Abstract][Full Text] [Related]
20. Fluconazole: optimized antifungal therapy based on pharmacokinetics.
Silling G
Mycoses; 2002; 45 Suppl 3():39-41. PubMed ID: 12690970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
